Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015

Juan Valle, et al.

Research output: Contribution to journalArticlepeer-review

11 Downloads (Pure)

Abstract

Background
The diagnosis of neuroendocrine neoplasms (NENs) is often delayed. This first UK population-based epidemiological study of NENs compares outcomes with non-NENs to identify any inequalities.

Methods
Age-standardised incidence rate (ASR), 1-year overall survival, hazard ratios, and standardised mortality rates (SMRs) were calculated for all malignant NENs diagnosed 2013–2015 from UK national Public Health records. Comparison with non-NENs assessed 1-year overall survival (1YS) and association between diagnosis at stage IV and morphology.

Results
A total of 15 222 NENs were identified, with an ASR (2013–2015 combined) of 8·6 per 100 000 (95% CI 8·5–8·7); 4·6 per 100 000 (95% CI, 4·5–4·7) for gastro-entero-pancreatic (GEP) NENs. The 1YS was 75% (95% CI, 73·9–75.4) varying significantly by sex. Site and morphology were prognostic.
NENs (predominantly small cell carcinomas) in the oesophagus, bladder, prostate, and female reproductive organs had a poorer outcome and were three times more likely to be diagnosed at stage IV than non-NENs.

Conclusion
Advanced stage at diagnosis with significantly poorer outcomes of some NENs compared with non-NENs at the same anatomical site, highlight the need for improved access to specialist services and targeted service improvement.
Original languageEnglish
Pages (from-to)966-972
JournalBJC
Volume121
Early online date25 Oct 2019
DOIs
Publication statusPublished - 26 Nov 2019

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Fingerprint

Dive into the research topics of 'Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015'. Together they form a unique fingerprint.

Cite this